PMV Pharmaceuticals, Inc. — Director's Dealing 2022

Apr 29, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PMV Pharmaceuticals, Inc. (PMVP)
CIK: 0001699382
Period of Report: 2022-04-27

Reporting Person: Mack David Henry (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-04-27	Common Stock	M	33000	$0.53	Acquired	79970	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-04-27	Employee Stock Option (right to buy)	$0.53	M	33000	Disposed	2025-05-11	Common Stock (33000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	147915	Indirect
Common Stock	80000	Indirect
Common Stock	56978	Indirect

Footnotes

F1: The shares are held of record by The Mack-Mulligan Revocable Trust. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein.

F2: The shares are held of record by the Stinson 2021 Irrevocable Trust. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein.

F3: The shares are held of record by the Mack/Mulligan 2020 Irrevocable Descendants' Trust. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein.

F4: The shares subject to the option are fully vested and immediately exercisable.

F5: Due to an administrative error, the Form 4 filed on May 24, 2021 overstated the number of derivative securities beneficially owned following the reported transaction by 6,207 shares and has been updated in this Form 4 to correct the error.